Ndibazza, Juliet and Mpairwe, Harriet and Webb, Emily L. and Mawa, Patrice A. and Nampijja, Margaret and Muhangi, Lawrence and Kihembo, Macklyn and Lule, Swaib A. and Rutebarika, Diana and Apule, Barbara and Akello, Florence and Akurut, Hellen and Oduru, Gloria and Naniima, Peter and Kizito, Dennison and Kizza, Moses and Kizindo, Robert and Tweyongere, Robert and Alcock, Katherine J. and Muwanga, Moses and Elliott, Alison M. (2012) Impact of Anthelminthic Treatment in Pregnancy and Childhood on Immunisations, Infections and Eczema in Childhood:A Randomised Controlled Trial. PLoS ONE, 7 (12). e50325 EP -.
|PDF - Published Version |
Available under License Creative Commons Attribution.
Download (656Kb) | Preview
Helminth infections may modulate immune responses to unrelated pathogens and allergens; these effects may commence prenatally. We addressed the hypothesis that anthelminthic treatment in pregnancy and early childhood would improve responses to immunisation and modulate disease incidence in early childhood with both beneficial and detrimental effects.A randomised, double-blind, placebo-controlled trial was conducted in Entebbe, Uganda [ISRCTN32849447]. In three independent randomisations, 2507 pregnant women were allocated to receive single-dose albendazole or placebo, and praziquantel or placebo; 2016 of their offspring were randomised to receive quarterly single-dose albendazole or placebo from age 15 months to 5 years. Primary outcomes were post-immunisation recall responses to BCG and tetanus antigens, and incidence of malaria, diarrhoea, and pneumonia; incidence of eczema was an important secondary outcome. Analysis was by intention-to-treat. Of 2345 live births, 1622 (69%) children remained in follow-up at age 5 years. 68% of mothers at enrolment, and 11% of five-year-olds, had helminth infections. Maternal hookworm and Schistosoma mansoni were effectively treated by albendazole and praziquantel, respectively; and childhood hookworm and Ascaris by quarterly albendazole. Incidence rates of malaria, diarrhoea, pneumonia, and eczema were 34, 65, 10 and 5 per 100 py, respectively. Albendazole during pregnancy caused an increased rate of eczema in the children (HR 1.58 (95% CI 1.15‚Äì2.17), p‚Ää=‚Ää0.005). Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR 0.85 (95% CI 0.73‚Äì0.98), p‚Ää=‚Ää0.03). There were no consistent effects of the interventions on any other outcome.Routine use of albendazole in pregnancy may not always be beneficial, even in tropical developing countries. By contrast, regular albendazole treatment in preschool children may have an additional benefit for malaria control where helminths and malaria are co-endemic. Given the low helminth prevalence in our children, the effect of albendazole on malaria is likely to be direct.Current Controlled Trials ISRCTN32849447
|Journal or Publication Title:||PLoS ONE|
|Additional Information:||Copyright: © 2012 Ndibazza et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Departments:||Faculty of Science and Technology > Psychology|
|Deposited On:||10 Dec 2012 14:49|
|Last Modified:||30 Sep 2013 15:25|
Actions (login required)